To further investigate whether PARP16 was associated with pathological cardiac hypertrophy in vitro, H9C2 cells or neonatal rat cardiomyocytes (NRCMs) were treated with pathologic hypertrophy agonist phenylephrine (PE), an α-adrenergic stimulant. The gene discussed is PARP16; the disease is cardiac hypertrophy.